IPO pricing is imminent — likely within 1-2 trading days. Watch for the final IPO price and first-day trading performance. The LYTAC platform targeting autoimmune/inflammatory diseases is novel but pre-revenue; initial float and institutional demand will set the tone. Monitor for post-IPO lockup expiration (typically 180 days) and any early insider registration statements.
Price Chart
Executive Summary
Lycia Therapeutics' IPO registration (S-1, File No. 333-299300) became effective on October 22, 2026. The company is now cleared to begin trading on Nasdaq under ticker LYCA, offering 14,700,000 shares at an expected price range of $16.00-$18.00 per share, with an underwriter option for an additional 2,205,000 shares. This marks the transition from a private clinical-stage biotech to a public company, with pricing expected imminently.
Key Facts
- IPO registration declared effective on October 22, 2026
- Offering 14,700,000 shares of common stock
- Expected IPO price range: $16.00 to $18.00 per share
- Underwriters granted 30-day option to purchase up to 2,205,000 additional shares
- Listing on Nasdaq Global Select Market under ticker LYCA
- Joint book-running managers: Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities
- Passive book-running manager: LifeSci Capital
- Company is a clinical-stage biotech focused on extracellular protein degradation (LYTAC platform)
Financial Impact
IPO expected to raise approximately $235-265 million before expenses (14.7M shares × $16-18 midpoint), plus up to ~$35-40 million from the overallotment option if exercised in full
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Expected IPO price range is wide ($16-$18) and final pricing may vary
- No public market exists yet — first-day volatility could be significant
- Underwriters' overallotment option adds 15% dilution if exercised
- Lockup expiration (standard 180 days) could pressure shares post-IPO
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003321 |
| Document: 9999999995-26-003321-index.html | 9999999995-26-003321 |
| Document: 9999999995-26-003321.txt | 9999999995-26-003321 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | $28.85 | awaiting T+1 | — | $28.85 (+0.00%) |
Oct 23, 2026 3d ago | 424B4 | $28.11 | awaiting T+1 | — | $28.85 (+2.63%) |
Oct 23, 2026 4d ago | EFFECT | $30.00 $28.85 | ▼ −3.83% | ▼ −4.54% | $28.85 (−3.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers